Sophie Piperno‐Neumann

Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade.

Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action

Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review

Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Data from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

Improved nationwide survival of sarcoma patients with a network of reference centers

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.

Divergent local and systemic antitumor response in primary uveal melanomas.

Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France - protocol of a prospective observational mixed-method study.

Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial.

Facilitating patient-oncologist communication in advanced treatment-resistant cancer: development and feasibility testing of a question prompt list.

Advances in the clinical management of uveal melanoma

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma

Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.

Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis

Data from Lack of Prognostic Value of <i>CTNNB<sub>1</sub></i> Mutation Profile in Desmoid-Type Fibromatosis